v3.26.1
Note 9 - License Agreements (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 171 Months Ended
Feb. 23, 2026
Feb. 10, 2025
Jan. 07, 2025
Jan. 07, 2024
Jul. 28, 2023
Feb. 28, 2026
Mar. 31, 2026
Mar. 31, 2026
Mar. 31, 2025
Jan. 31, 2012
Precision BioSciences, Inc. [Member]                    
Investment Purchased Balance Shares (in shares)     220,712              
License Agreement, Percentage of Premium on Equity Investment 200.00%                  
License Agreement, Share Price, Trading Days (Day) 30 years   30 days              
License Agreement, Payment, Percentage of Weighted Average Share Price     200.00%              
Precision BioSciences, Inc. [Member] | Maximum [Member]                    
Investment Purchased Balance Shares (in shares) 201,504     2,920,816            
Product [Member]                    
Accounts Receivable, after Allowance for Credit Loss             $ 27,200 $ 27,200 $ 13,400  
L F B License Agreement [Member]                    
License And Collaboration Agreement, Expenses Incurred               31,000    
Accounts Payable             0 0    
Royalty Expense             20,600      
Accrued Royalties             20,600 20,600    
L F B License Agreement [Member] | License Agreement Terms [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)                   15 years
Commercialization Agreement With Neuraxpharm [Member]                    
License and Collaboration Agreements, One-time, Non-refundable Payment         $ 140,000   204,900      
Additional Amount Receivable on Achievement of Pre-specified Milestones         $ 492,500          
Royalty Percentage on Net Product Sales         30.00%          
Revenues             2,700      
Deferred Revenue             24,100 24,100    
Accounts Receivable, after Allowance for Credit Loss             $ 800 $ 800    
Briumvi Ublituximab [Member] | Product [Member]                    
Product Sales, Net Related to Performance Obligations         $ 12,500          
Precision License Agreement [Member]                    
Additional Amount Receivable on Achievement of Pre-specified Milestones           $ 286,000        
License Agreement, Amount Paid Upfront $ 7,500     $ 7,500   7,500        
License Agreement, Amount Paid Upfront, Cash 5,250     5,250   5,250        
License Agreement, Amount Paid Upfront, Equity Investment $ 2,250     2,250   $ 2,250        
License Agreement, Deferred Payment       $ 2,500            
License Agreement, Percentage of Premium on Equity Investment       100.00%            
License Agreement, Share Price, Trading Days (Day)       30 days   30 days        
License Agreement, Payment, Percentage of Weighted Average Share Price           200.00%        
Term After First Commercial Sale (Year)           10 years        
Precision License Agreement [Member] | Maximum [Member]                    
Investment Purchased Balance Shares (in shares)           201,504        
Strategic Platform License Agreement with MaxCyte, Inc. [Member]                    
License Agreement, Amount Paid Upfront   $ 1,000                
License Agreement, Additional Milestone Payments   13,000                
Licensing Agreement, Annual License Fee   $ 200                
License Agreement, Term (Year)   10 years                
License Agreement, Renewal Term (Year)   5 years                
License Agreement, Written Notice Period (Day)   90 days